GlassScriptPhysician profile
Aimee Adams
NPI 1740620970
$7,799.95
in general payments reported to CMS, 2019-2025
26 companies · $3,150 in 2025
The $3,150 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $595 · 2022: $1,008 · 2023: $1,552 · 2024: $1,495 · 2025: $3,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,895 · Consulting Fee: $760 · Education: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,895.48 |
| Consulting Fee | $760.00 |
| Education | $541.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,227.18 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,142.79 | 2021-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $1,022.99 | 2022-2025 | Sotyktu, Sprycel |
| Genzyme Corporation | $493.54 | 2022-2025 | |
| Galderma Laboratories, L.P. | $471.59 | 2021-2025 | Nemluvio |
| Janssen Biotech, INC. | $462.38 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $379.30 | 2021-2025 | |
| Leo Pharma INC. | $368.28 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $329.26 | 2022-2025 | Otezla, Otezla, Actimmune |
| Novartis Pharmaceuticals Corporation | $303.75 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $292.68 | 2023-2024 | Zoryve |
| Allergan, INC. | $239.37 | 2021-2022 | |
| Lilly USA, LLC | $203.44 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $149.64 | 2024 | Cabtreo |
| Dermavant Sciences, INC. | $131.90 | 2023 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $124.74 | 2023 | Opzelura |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Pfizer INC. | $80.37 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $78.14 | 2024-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $71.97 | 2022-2025 | |
| Botanix Sb INC | $39.70 | 2025 | Sofdra |
| Solta Medical, A Division of Bausch Health US, LLC | $21.93 | 2024 | Clear+Brilliant |
| Verrica Pharmaceuticals INC. | $19.80 | 2023 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.81 | 2024 | Spevigo |
| Kyowa Kirin, INC. | $15.32 | 2025 | |
| Boston Scientific Corporation | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.